Defunct Company
Total Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
308
NCT02002208
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
Phase: Phase 2
Role: Lead Sponsor
Start: Oct 31, 2013
Completion: Feb 29, 2016
NCT02660489
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
Role: Collaborator
Start: Jan 31, 2015
Completion: Feb 28, 2018
NCT02316912
First in Man Evaluation of Single and Multiple Doses of Oral ATX2417
Phase: Phase 1
Start: Feb 28, 2015
Completion: Apr 30, 2016
NCT02341521
Evaluation of Metabolic Profile of OC000459
Start: Mar 31, 2015
Completion: May 31, 2015
NCT02560610
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
Start: Sep 30, 2016
Completion: Aug 2, 2018